Unlocking the skin’s potential as a therapeutic vector

Deliver a range of molecules into the skin and systemic circulation using Avro’s passive ionic liquid platform

Learn More
A clinical stage biotech redefining the skin’s potential as a therapeutic vector.
OUR Pipeline

Pipeline Details

PROGRAM
INDICATION
DISCOVERY        FORMULATION         PRE-CLINICAL         PHASE I         PHASE II         PHASE III         NDA
AVR-235
Psoriasis
PHASE II
AVR-335
Atopic Dermatitis (AD)
PHASE I
AVR-101
Parkinson’s Disease (PD)
PRE-CLINICAL
AVR-201
ALS
PRE-CLINICAL
AVR-BIO
Undisclosed
DISCOVERY
AVR-RNA
Undisclosed
DISCOVERY

Avro Life Science’s pipeline is focused on improving patient outcomes and quality of life by delivering high-value medication through the skin.

Avro’s passive topical delivery platform serves to redefine the skin’s potential as a therapeutic vector, enabling the systemic delivery of small molecules and peptides, and the localized delivery of larger, complex therapeutics, including proteins, antibodies, nucleic acids, CRISPR, and more into the skin, without the use of microneedles or other invasive technology.

Avro’s vision is to enhance the delivery of a range of existing therapeutics, while unlocking the potential of the next generation of dermal therapies and novel modalities in the same way that lipid nanoparticle technology unlocked the potential of mRNA vaccines.

Our systemic drug delivery portfolio focuses on translating non-orally available small molecules and peptides (often delivered subcutaneously/intravenously) into 1-7 day use transdermal patches (dose-dependent). Current programs in PD and ALS address neurologically and/or motor-compromised elderly populations which are underserved by today’s invasive and inaccessible delivery methods.

Our topical drug delivery portfolio serves to enable the in-situ dermal delivery of novel therapeutic modalities like nucleic acid therapeutics (ASOs, siRNAs, mRNAs, CRISPR-RNPs) for gene editing and therapy in the skin, with curative intent. Our topical platform also enables the targeted delivery of biologics like proteins and antibodies for localized therapeutic effects with reduced side effect profiles and higher site-specific efficacy.

Our NCE portfolio utilises PEGylated small molecules and novel targets (TrkA) to address some of the most prevalent inflammatory skin conditions such aspsoriasis, and atopic dermatitis.

OUR Mission

OmniDerm™

Avro is a leading preclinical stage pharmaceutical company developing OmniDerm(™)
a platform transdermal technology for the passive delivery of small drug molecules. 

Avro’s novel polymer utilizes cutting-edge advances in biomaterials engineering and micro-encapsulation technology, to hold and deliver a wide range of drugs over a 1-7 day timespan, where transdermal delivery was previously thought to be impossible. 

Our mission is to improve patient health outcomes and quality of life through medication compliance and adherence afforded by effective drug delivery solutions.

To learn more, or chat about partnering, send us a note at: partnering@avrolifesci.com

OUR Solution

Accessible Transdermal Tech

One Size Fits All

One-size-fits-all versatile platform allowing for encapsulation and delivery of a wide variety of different small molecule drugs, inplace of existing “lock and key” patches available on the market, requiring a custom polymer for each drug.

Cost-effective Manufacturing

Cost-effective, tunable, and easily scalable manufacturing processes using easily sourced and non-irritant, non-toxic materials and known industrial methods. Results in a single layer, drug-in-adhesive, sweatproof, waterproof, non-irritant patch with few failure modes during production due to the polymer’s fundamental chemistry.

Eliminating Complex Systems

Relies on fundamental materials science breakthroughs enabled by recent advances in understanding of biomaterial interactions and microencapsulation methods. Eliminates the need for expensive microneedles, lock and key patches, and complex manufacturing processes, allowing Avro to succeed where pharma has failed

OUR TEAM

Shakir Lakhani
Co-founder, CEO
Keean Sarani
Co-founder, COO
Frank LaRonde MD, PhD
Senior Scientist
Samantha Shortall
Scientist
Mahdi Roohnikan
Scientist
Shirley Wang
Research Associate
Drew Davidson
Research Associate
Andrew Mendonca
Research Associate

Advisors

Dr. Christopher Rhodes
CEO, Drug Delivery Experts, Prev. Exec. Director of Pharmaceutical R&D at Amylin Pharmaceuticals
Alasdair Thong
Prev. Director of Bayer AG Venture Investments, Investor at Index Ventures, Founding team at Medicxi
Dr. James Wright
Prev. Founder of Civitas Therapeutics (acq. by Acorda Tx for $525M), SVP at Alkermes, VP of Pharmaceutical Sciences at Takeda
Dr. Elizabeth Iorns
CEO of Science Exchange, Stanford Med METRICS Advisory Board member, YC Expert
Dr. Maleek Jamal
Prev. Lead, BCG Healthcare Practice, Clinical Trials Lead at P&G
Dr. Muhammad Mamdani
Director of Li Ka Shing Centre at St. Michael’s Hospital, Prev. Director of US Outcomes Research at Pfizer
Who Supports us

Affiliations

BayerY CombinatorThiel FellowshipVelocityCreative Destruction LabUniversity of WaterlooMitacsOCECalifornia Life Sciences
GET IN TOUCH

Contact Us

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.